Integrin αvβ3 has been implicated in multiple aspects of tumor progression and metastasis. Many tumors have high expression of αvβ3 that correlates with tumor progression. Therefore, αvβ3 receptor is an excellent target for drug design and delivery. We have discovered a series of novel αvβ3 antagonists utilizing common feature pharmacophore models. Upon validation using a database of known αvβ3 receptor antagonists, a highly discriminative pharmacophore model was used as a 3D query. A search of a database of 600 000 compounds using the pharmacophore Hypo5 yielded 832 compounds. On the basis of structural novelty, 29 compounds were tested in αvβ3 receptor specific binding assay and four compounds showed excellent binding affinity. A limited SAR analysis on the active compound 26 resulted in the discovery of two compounds with nanomolar to subnanomolar binding affinity. These small-molecule compounds could be conjugated to paclitaxel for selective delivery to αvβ3 positive metastatic cancer cells.

Discovery of Small Molecule Integrin αvβ3 Antagonists as Novel Anticancer Agents

AIELLO F;A. GAROFALO;
2006-01-01

Abstract

Integrin αvβ3 has been implicated in multiple aspects of tumor progression and metastasis. Many tumors have high expression of αvβ3 that correlates with tumor progression. Therefore, αvβ3 receptor is an excellent target for drug design and delivery. We have discovered a series of novel αvβ3 antagonists utilizing common feature pharmacophore models. Upon validation using a database of known αvβ3 receptor antagonists, a highly discriminative pharmacophore model was used as a 3D query. A search of a database of 600 000 compounds using the pharmacophore Hypo5 yielded 832 compounds. On the basis of structural novelty, 29 compounds were tested in αvβ3 receptor specific binding assay and four compounds showed excellent binding affinity. A limited SAR analysis on the active compound 26 resulted in the discovery of two compounds with nanomolar to subnanomolar binding affinity. These small-molecule compounds could be conjugated to paclitaxel for selective delivery to αvβ3 positive metastatic cancer cells.
2006
Pharmacology; cancer research
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11770/151988
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 120
  • ???jsp.display-item.citation.isi??? 107
social impact